Development and validation of a risk scoring model to predict net adverse cardiovascular outcomes after primary percutaneous coronary intervention (PCI) in patients pretreated with 600 mg clopidogrel, rationale and design of the RISK-PCI study

Clinical Center of Serbia (Serbia)0 个研究点目标入组 1,750 人开始时间: 2008年9月30日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Both males and females, 18 years of age or older
•2. Chest discomfort persisting for more than 20 minutes
•3. Presentation within 12 hours after the onset of symptoms
•4. ST elevation in two contiguous leads of at least 0.2 mV in leads V2?V3 and/or of at least >0.1 mV in other leads, or new bundle branch block
•5. Cardiac troponin exceeding upper reference limit at admission and/or 24 hours later

•1. Refusal to give consent for invasive treatment
•2. Contraindications for dual antiplatelet therapy or contrast agents (active or recent internal bleeding, history of bleeding after non-steroid anti-inflammatory agents, known bleeding diathesis, allergy, intracerebral mass or aneurysm, platelet count of <100,000/mm^3
•3. Cardiogenic shock at admission
•4. Noncardiac conditions that could limit life expectancy to less than 1 year or that might interfere with compliance with the protocol (active cancer, significant liver or renal disease [creatinine clearance <30 ml/min], significant psychiatric disorders)
•5. Planned elective surgery necessitating interruption of treatment with thienopyridines during the first 6 months after enrolment

发起方

Clinical Center of Serbia (Serbia)